Pharmaceuticals, Biotechnology and Life Sciences
Former Allergan boss David Pyott signed as special advisor to Sienna Biopharmaceuticals, a privately held, clinical-stage medical dermatology and aesthetics company.
TopiVert Pharma has finished dosing of the first subjects in a Phase 1 study of its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).
US Food and Drug Administration (FDA) has approved AstraZeneca’s once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes.
Oxford BioMedica, a leading gene and cell therapy group, announces that Stuart Paynter will join Oxford BioMedica as Chief Financial Officer to succeed Tim Watts, who has decided to retire from full time executive roles.
Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).
Former Pfizer CEO and chairman Jeff Kindler will be joining privately held Israel’s drugmaker Pharma Two B’s board of directors, as the company completed its third round of financing, raising $30 million, with Israel Biotech Fund (IBF) leading the procedure. Jeff Kindler is a member of Israel Biotech Fund’s Venture Advisory Team.
Allergan’s Vice President of Investor Relations, Lisa DeFrancesco, has resign after being nearly 8 years of leading the Investor Relations of the company.
Argenx and Shire have extended their strategic partnership from 2014 to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.
Valeant Pharmaceuticals`s subsidiary, Bausch + Lomb, and Nicox have resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution, 0.024%.